All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On December 22, 2022, it was announced that mosunetuzumab-axgb, a CD20 × CD3 T cell-engaging bispecific antibody, had received U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after ≥2 prior lines of systemic therapy. This approval marks a major milestone for this patient group, who have previously had limited treatment options.1
The approval is based on key results from the phase II GO29781 study (NCT02500407), previously reported on the Lymphoma Hub, in which mosunetuzumab demonstrated high and durable response rates in heavily pretreated patients with R/R FL, including patients at high risk of progression and those refractory to previous treatment. Latest results from the study demonstrated overall and complete response rates of 80% and 60%, respectively. Responses were maintained for ≥18 months in 57% of patients. The most common adverse event was cytokine release syndrome, which was observed in 39% of patients for a median duration of 3 days.1
This approval follows the European Commission (EC) approval in June 2022, previously reported on the Lymphoma Hub.
https://www.businesswire.com/news/home/20221221005003/en/FDA-Approves-Genentech%E2%80%99s-Lunsumio-a-First-in-Class-Bispecific-Antibody-to-Treat-People-With-Relapsed-or-Refractory-Follicular-Lymphoma. Published Dec 22, 2022. Accessed Dec 23, 2022.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox